The Global Antibiotic Resistance Market size was valued at USD 10.1 billion in 2020 and is expected to reach USD 14.4 Billion over the forecast period. It is anticipated to register a CAGR of 7% from 2020 to 2027. High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market.
Antibiotics are antimicrobial substance which is used to fight against the bacterial infection. They are also used to cure many conditions such as strep throat, sinus infections, urinary tract infections, ear infections, pneumonia, skin infections, and others. Antibiotics are classified on the basis of chemical structures, spectrum of activity and mode of action. The ability to resist the bacterial infection is termed as antibiotics resistance. It is a major concern worldwide. Major pharmaceutical companies on the forefront are involved in the development of broad-spectrum antibiotics. For instance, in 2018, Acurx Pharmaceuticals introduced ACX-362E, which is the US Food and Drug Administration (FDA) approved antibiotic candidate, designated as Qualified Infectious Disease Product (QIDP) with Clostridium Difficile Infection (CDI).
Emergence of multi-drug resistant pathogens and high burden of antibiotic-resistant infections are the major factors driving the market. In addition, several biotech companies are developing therapies for antibiotic resistance which is fuelling the growth of antibiotic resistance market. Fewer profit margins for marketed drugs and lower return on investments may hamper the growth of antibiotic resistance market. However, funding from international organizations serves as a catalyst in developed markets. Financial support for biotech companies to complete early-stage development of their novel therapies for antibiotic resistant infections are major subsidizing factors boosting the growth of the antibiotic resistance market.
Antibiotics are antimicrobial substance which is used to fight against the bacterial infection. They are also used to cure many conditions such as strep throat, sinus infections, urinary tract infections, ear infections, pneumonia, skin infections, and others. Antibiotics are classified on the basis of chemical structures, spectrum of activity and mode of action. The ability to resist the bacterial infection is termed as antibiotics resistance. It is a major concern worldwide. Major pharmaceutical companies on the forefront are involved in the development of broad-spectrum antibiotics. For instance, in 2018, Acurx Pharmaceuticals introduced ACX-362E, which is the US Food and Drug Administration (FDA) approved antibiotic candidate, designated as Qualified Infectious Disease Product (QIDP) with Clostridium Difficile Infection (CDI).
Emergence of multi-drug resistant pathogens and high burden of antibiotic-resistant infections are the major factors driving the market. In addition, several biotech companies are developing therapies for antibiotic resistance which is fuelling the growth of antibiotic resistance market. Fewer profit margins for marketed drugs and lower return on investments may hamper the growth of antibiotic resistance market. However, funding from international organizations serves as a catalyst in developed markets. Financial support for biotech companies to complete early-stage development of their novel therapies for antibiotic resistant infections are major subsidizing factors boosting the growth of the antibiotic resistance market.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
